 12. Concurrent chemoradiation is permitted as consolidative therapy. The following concurrent therapies are permitted: Tyrosine kinase inhibitors i.e. erlotinib - can be delivered with both hypofractionated 3 Gy per fraction and standard fractionated radiation therapy 3 Gy per fraction; platinum-based chemotherapy - standard fractionated radiation therapy 3 Gy per fraction 